Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Sells S. Pneumoniae Patents to Aventis, Ends Research for Amgen

NEW YORK, Jan. 9 (GenomeWeb News) - GenomeTherapeutics has sold its pending Streptococcus pneumoniae patent applications to Aventis Pasteur, the company said today.

 

Aventis Pasteur, the vaccines business of Aventis, paid Genome Therapeutics $3 million for the U.S. patent applications, which relate to gene and protein sequences from the S. pneumoniae genome. Genome Therapeutics, based in Waltham, Mass., will retain certain rights relating to its pathogen genetic sequence database and its infectious disease diagnostics development program.

 

In addition, Genome Therapeutics said it has concluded a bone disease research project with Amgen, which led to the discovery of a novel gene. The company, which announced its plan to merge with Genesoft Pharmaceuticals in November, said it continues to reduce its investment in early-stage discovery research projects.

 

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.